Immunotherapy Drugs Market Size by Therapy Area, By End-User, By Type of Drugs, By Geographic Scope and Forecast

Immunotherapy Drugs Market Valuation - 2024-2031

The demand for immunotherapy drugs is rising as these treatments offer new hope for patients with various forms of cancer, autoimmune diseases, and infectious conditions. Unlike traditional therapies, immunotherapy works by harnessing the body's immune system to recognize and fight diseases, making it a powerful alternative that can target specific cells with potentially fewer side effects. As cancer rates continue to climb globally, the need for effective treatments with durable responses has driven research and adoption in this field. The market size surpass USD 256.78 Billion valued in 2024 to reach a valuation of around USD 568.71 Billion by 2031.

Immunotherapy drugs such as checkpoint inhibitors, CAR T-cell therapies, and monoclonal antibodies have shown significant success in clinical trials, further propelling their demand and integration into standard treatment protocols. The rising demand for cost-effective and immunotherapy drugs is enabling the market grow at aCAGR of 10.45% from 2024 to 2031.

Immunotherapy Drugs Market: Definition/ Overview

Immunotherapy drugs are a class of treatments designed to enhance or modify the body's immune response to recognize and attack disease-causing cells. Unlike traditional treatments, which directly target the disease, immunotherapy leverages the immune system to target and destroy abnormal cells, often with a focus on specific markers that distinguish them from healthy cells. These drugs encompass a variety of approaches, including checkpoint inhibitors, CAR T-cell therapies, monoclonal antibodies, and cytokines, each designed to either boost immune responses or reduce immune tolerance to disease cells. Immunotherapy has proven especially effective in treating cancers, chronic infections, and certain autoimmune diseases by creating a more targeted response, with the potential for fewer side effects compared to conventional therapies.

The future scope of immunotherapy drugs is highly promising as research continues to expand its applications across more diseases. Technological advancements in genomics and molecular biology are driving the development of next-generation immunotherapies, including personalized treatments based on an individual's genetic profile.

The use of immunotherapy is also expected to increase in treating autoimmune conditions and infectious diseases, moving beyond its initial focus on oncology. As the understanding of immune pathways grows, the pharmaceutical industry is investing heavily in immunotherapy R&D, which, combined with supportive regulatory policies, is likely to broaden its impact and availability. This trajectory suggests immunotherapy will play a pivotal role in the future of medicine, providing more targeted and durable solutions for complex diseases.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

How Will the Rising Cancer Incidence Worldwide Drive the Immunotherapy Drugs Market?

The rising global incidence of cancer is a significant driver for the immunotherapy drugs market. With cancer responsible for nearly 10 million deaths in 2020 and new cases projected to increase by 60% by 2040, according to the WHO, there is a growing demand for effective treatments. Immunotherapy drugs, especially checkpoint inhibitors, have demonstrated promising results with up to 40% response rates in cancers like melanoma, as reported by the American Cancer Society, leading to increased adoption of these therapies to improve patient outcomes.

The growing prevalence of autoimmune diseases is a major driver of the Immunotherapy Drugs Market. According to the NIH, over 24 million people in the United States are affected by autoimmune disorders, and the American Autoimmune Related Diseases Association (AARDA) notes an annual increase of 19% in cases. With women twice as likely to develop these conditions, the demand for effective treatments, such as immunotherapy drugs, is rising rapidly. This trend underscores the need for innovative therapies to manage and treat autoimmune diseases, thus fueling market growth.

How Does the High Cost of Treatment Hamper the Growth of the Immunotherapy Drugs Market?

The high cost of treatment is a significant factor hampering the growth of the Immunotherapy Drugs Market. Immunotherapy treatments are often expensive due to the complex research, development, and production processes involved, making them less accessible to many patients, especially those without adequate insurance coverage. This financial barrier limits patient access to these therapies, restricting market growth as affordability issues deter widespread adoption despite the potential benefits of immunotherapy in treating various diseases.

Limited efficacy in certain patient populations can hamper the growth of the Immunotherapy Drugs Market. Immunotherapy is not universally effective, as some patients may not respond well due to genetic, environmental, or biological factors, which restricts its overall impact and adoption. This variability in treatment outcomes reduces confidence among healthcare providers and patients, slowing down the acceptance and widespread use of immunotherapy drugs and ultimately affecting market growth.

Category-Wise Acumens

Will the Proven Efficacy Propel the Checkpoint Inhibitors Segment for the Immunotherapy Drugs Market?

The checkpoint inhibitors segment is dominating the immunotherapy drugs market. The proven efficacy of checkpoint inhibitors is propelling the checkpoint inhibitors segment in the immunotherapy drugs market. These drugs have shown remarkable success in treating various cancers, especially by enhancing the body's immune response to target and destroy cancer cells more effectively. Their ability to improve survival rates in challenging cases, such as advanced melanoma and lung cancer, has driven strong demand from healthcare providers and patients alike. With ongoing research expanding their use across different cancer types, the efficacy of checkpoint inhibitors continues to strengthen their role in cancer therapy.

The favorable safety profile is propelling the checkpoint inhibitors segment in the Immunotherapy Drugs Market. Checkpoint inhibitors target specific pathways in cancer cells, allowing the immune system to attack cancer more effectively with fewer side effects compared to traditional therapies like chemotherapy. This targeted approach reduces the risk of widespread toxicity, making these drugs safer and better tolerated by patients. As a result, the preference for checkpoint inhibitors is growing, particularly for long-term cancer treatment, driving their demand in the immunotherapy drugs market.

Will the High Prevalence of Diseases Promote the Healthcare Institutions Segment for the Immunotherapy Drugs Market?

The healthcare institutions segment is ruling the immunotherapy drugs market. The high prevalence of diseases, particularly cancer and autoimmune disorders, is promoting the healthcare institutions segment in the immunotherapy drugs market. As the incidence of these diseases rises globally, healthcare institutions are increasingly adopting advanced immunotherapy treatments to improve patient outcomes. Immunotherapy drugs, such as checkpoint inhibitors and monoclonal antibodies, offer promising alternatives to traditional treatments, attracting healthcare providers seeking more effective therapies. The growing demand for innovative treatments within hospitals and clinics is driving the expansion of immunotherapy drug usage in healthcare settings.

Advanced medical infrastructure is promoting the Healthcare Institutions segment in the Immunotherapy Drugs Market. With improved healthcare facilities, technology, and expertise, institutions are better equipped to administer complex immunotherapies, including precision medicine and advanced biologics. The availability of cutting-edge diagnostic tools and treatment protocols enables healthcare providers to deliver these therapies more effectively, improving patient outcomes. As hospitals and clinics enhance their capabilities, the demand for innovative immunotherapy drugs continues to rise, driving growth in this segment.

Country/Region-wise Acumens

Will the Disease Prevalence and Patient Population Accelerate the North American Region for the Immunotherapy Drugs Market?

North America's dominance in the immunotherapy drugs market is driven by several factors. Disease prevalence and a large patient population are accelerating the Immunotherapy Drugs Market in North America. In 2023, the American Cancer Society reported around 1.9 million new cancer diagnoses, with immunotherapy as a primary treatment option, and the National Cancer Institute noted that 40% of U.S. cancer patients are eligible for these therapies. Additionally, autoimmune diseases affect approximately 23.5 million Americans and are rising by 4-7% annually. This high prevalence of cancer and autoimmune conditions creates a substantial demand for immunotherapy treatments, driving market growth in the region.

Advanced healthcare infrastructure is accelerating the Immunotherapy Drugs Market in North America. The region boasts over 1,500 cancer centers offering immunotherapy treatments, and 89% of oncologists now prescribe immunotherapy as a first-line option for eligible patients. Additionally, expanded Medicare coverage for CAR T-cell therapy, now covering 85% of eligible patients, makes these innovative treatments more accessible. This robust infrastructure and supportive coverage landscape enhance patient access and adoption of immunotherapy, driving significant market growth in North America.

Will the Healthcare Infrastructure Improvements Expand the Asia Pacific region for Immunotherapy Drugs Market?

Asia Pacific is rapidly growing in the immunotherapy drugs market. Healthcare infrastructure improvements are driving the Immunotherapy Drugs Market in the Asia Pacific region. China's "Healthy China 2030" initiative emphasizes enhanced cancer care and the development of immunotherapies, while India's National Health Policy 2017 aims for universal health coverage, including access to advanced cancer treatments. Additionally, Japan's substantial investment of JPY 1.1 trillion in healthcare R&D, focusing on innovative oncology therapies, strengthens the region's capacity to support and expand immunotherapy options. These initiatives collectively boost accessibility, research, and adoption of immunotherapies, accelerating market growth in the Asia Pacific.

A supportive regulatory environment is accelerating the Immunotherapy Drugs Market in the Asia Pacific region. In 2023, China's National Medical Products Administration (NMPA) approved 15 new immunotherapy drugs, signaling strong support for these treatments. India's Central Drugs Standard Control Organization (CDSCO) has streamlined approval processes specifically for immune-oncology therapies, while Japan's Pharmaceuticals and Medical Devices Agency (PMDA) has introduced expedited review pathways for breakthrough immunotherapies. These regulatory advancements facilitate faster market entry and access, boosting the availability and adoption of immunotherapy drugs across the Asia Pacific.

Competitive Landscape

The immunotherapy drugs market is a dynamic and competitive space, characterized by a diverse range of players vying for market share. These players are on the run for solidifying their presence through the adoption of strategic plans such as collaborations, mergers, acquisitions, and political support.

The organizations are focusing on innovating their product line to serve the vast population in diverse regions. Some of the prominent players operating in the immunotherapy drugs market include:

• Roche
• Merck & Co.
• Bristol-Myers Squibb
• Novartis
• Pfizer
• Amgen
• AstraZeneca
• Gilead Sciences
• Johnson & Johnson
• GlaxoSmithKline

Latest Developments

• In September 2023, NextCure announced the initiation of a Phase I/II trial (NCT03665285) to evaluate the safety and tolerability of NC318 as a potential treatment for advanced or metastatic solid tumors. The trial includes assessments for conditions such as head and neck squamous cell carcinoma, non-small cell lung cancer, and ovarian cancer.
• In January 2022, Immunocore Ltd, a biotechnology company, got FDA clearance for tebentafusp-tebn (Kimmtrak), a bispecific gp100 peptide-HLA-directed CD3 T cell engager, for adult patients with unresectable or metastatic uveal melanoma and HL:01.